It was also reported that siRNA-induced knockdown of GRP78 restores the antiestrogen sensitivity in the tamoxifen-resistant breast cancer cells (MCF-7/LCC9) [137]; combining GRP78 inhibitors with the antiestrogen therapy has been suggested for better targeting breast cancer [197,198]. This evidence concerns the gene HSPA5 and breast carcinoma.